Yesterday in court

a federal judge refused to dismiss the cagrisema lawsuit — and the weight-loss numbers are the reason

On July 29, 2026, U.S. District Judge Robert Kirsch, sitting in the District of New Jersey, declined to dismiss a shareholder fraud lawsuit against Novo Nordisk — and the case turns almost entirely on a five-percentage-point gap in weight loss. The lawsuit covers a class period running from November 2, 2022, through December 19, 2024. Plaintiffs allege that Novo Nordisk publicly promoted CagriSema's "tolerability" while concealing a key change to the REDEFINE-1 trial protocol: the company allowed participants to self-titrate their doses rather than follow a fixed escalation schedule. The result was that only 57% of enrolled participants actually reached the target dose. When Novo Nordisk reported REDEFINE-1 results in December 2024, CagriSema showed an average weight loss of 20.4%. Wall Street had priced in at least 25%. The company's stock fell 17.8% in a single session — one of its worst days in years (CNBC, July 29 2026: https://www.cnbc.com/2026/07/29/novo-nordisk-lawsuit-cagrisema-weight-loss-drug.html; FierceBiotech, July 29 2026: https://www.fiercebiotech.com/biotech/novo-nordisk-fails-dismiss-lawsuit-over-cagrisema-readout). Judge Kirsch allowed two categories of claims to proceed: statements about tolerability and statements about the REDEFINE-1 clinical protocols. The fraud theory, in plain terms, is that the company knew the dosing change would make the drug look better-tolerated but worse at its main job, and did not say so.

The actual mechanism

cagrilintide is a long-acting amylin analog — and amylin is not the same as glp-1

Cagrilintide is a synthetic analog of amylin — a hormone the pancreas releases alongside insulin after a meal. Amylin's job is distinct from GLP-1's: where GLP-1 receptor agonists like semaglutide work primarily by slowing gastric emptying and signaling satiety through the gut-brain axis, amylin acts directly on receptors in the hypothalamus and brainstem to reduce food intake and regulate glucose. The theory behind CagriSema (cagrilintide + semaglutide) is that the two peptides hit the same biological endpoint — eat less, weigh less — through complementary pathways. Semaglutide handles the GLP-1 side; cagrilintide handles the amylin side. Preclinical models suggested the combination would be more than additive. Cagrilintide monotherapy showed meaningful but modest results on its own: approximately 11.8% weight reduction versus 2.3% for placebo over 68 weeks in the pivotal REDEFINE trial, according to the NEJM publication of the obesity data (https://www.nejm.org/doi/full/10.1056/NEJMoa2502081). That number is the reason the combination was expected to do substantially better.

The market pitch

the obesity market wanted a 25-percent drug — cagrisema's redefine-1 came in at 20

The obesity drug market is shaped by one number more than any other: 25%. That figure — variously attributed to analyst projections and Novo Nordisk's own promotional framing — was the weight-loss expectation investors, physicians, and payers built into their models for CagriSema. The actual REDEFINE-1 result for the combination (20.4%) was not disqualifying on its own. A 20% average weight loss from a once-weekly injection is clinically meaningful — the FDA's threshold for obesity drug approval is substantially lower than that. But the market was comparing CagriSema to Eli Lilly's tirzepatide (Zepbound/Mounjaro), which showed roughly 22.5% weight loss in its pivotal trial and has now beaten CagriSema in a direct head-to-head comparison. That is the competitive reality Novo Nordisk faces heading into what is expected to be a Q4 2026 FDA decision on the NDA it filed in late 2025: a drug that works, but trails the market leader on the only metric anyone is tracking, and is now entangled in a securities lawsuit over whether the trial that produced that number was conducted cleanly.

What the data shows

three phase-3 diabetes trials met their endpoints — that is what the nda is actually built on

The legal trouble centers on the obesity indication — but Novo Nordisk's NDA for CagriSema is broader than that. The company also submitted Phase 3 data for CagriSema in type 2 diabetes management, where the picture is considerably cleaner. The REIMAGINE 1, 2, and 3 trials, presented at the American Diabetes Association's 2026 annual meeting in New Orleans in June, all met their primary HbA1c endpoints. CagriSema showed 1.91% HbA1c reduction — superior to semaglutide 2.4 mg alone — along with meaningful weight loss in the type 2 diabetes population (NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2502082). Two new ClinicalTrials.gov registrations from 2026 suggest Novo Nordisk is already thinking about next-generation delivery: one pharmacokinetic study comparing cagrilintide formulation variants (https://clinicaltrials.gov/study/NCT07597018) and one evaluating tolerability in patients who cannot tolerate standard GLP-1 receptor agonist therapy (https://clinicaltrials.gov/study/NCT07607587). The second study is notable — if cagrilintide's amylin-pathway mechanism causes fewer GI side effects than GLP-1 mono-agonists, it may carve out a distinct patient population regardless of what happens with the obesity numbers.

Early human — PeptideFactCheck stance

real mechanism, real trial data, and a lawsuit that asks what the company knew about dosing

PeptideFactCheck rates cagrilintide as Early human — which means real mechanism and real Phase 3 trial data, but not yet the kind of settled certainty that warrants the Human-supported or Approved labels. What earns the Early human rating: The NEJM papers are published. The FDA has a complete NDA to review. Amylin biology is well-characterized, not speculative. This is not a peptide that has only been tested in rodents or in small early-phase cohorts. What keeps it from a higher rating: The obesity pivotal trial is under active legal dispute about whether the trial itself was properly conducted. A protocol change that allowed patient self-titration — and may have produced lower dropout but also lower measured efficacy — is exactly the kind of confound that makes a single pivotal trial's headline number hard to interpret cleanly. An FDA review that takes the trial data at face value may still approve this drug. A review that looks harder at the self-titration question may ask for more. The science is real. The lawsuit asks whether the company was straight with investors about what the science was actually measuring — and as of July 29, 2026, a federal judge has decided that question is worth taking to trial.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.